Monday November 23 2009 | Biotechnology feed | All feeds

Novartis

http://www.us.novartis.com

Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients

Tuesday 20th of October 2009 1:15

12. Jabbour E, Cortes J, Kantarjian H, et al. Molecular Monitoring in Chronic Myeloid Leukemia Response to Tyrosine Kinase Inhibitors and Prognostic Implications. Cancer. DOI10.1002/cncr.23427. Published online 17 March 2008.


    Media Contacts

    Media only:                            Investors only:
    Sabrina Oei                            Richard Jarvis
    Novartis Oncology                      Novartis Corporation
    P: +1 862 778 6387                     P: +1 212 830 2433

    Dana Kahn Cooper
    P: +1 732 817 1800
    C: +1 732 239 6664

SOURCE Novartis

Browse other news from this organisation: Novartis

Source PR Newswire

PR Newswire Logo
www.prnewswire.co.uk

Browse news from 2009

Download PDF PDF Version

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.